The Newsweek rankings, compiled based on evaluations from medical professionals and experts across multiple countries, underwent rigorous review by an advisory board before final publication. Samsung Seoul Hospital distinguished itself across several medical specialties. In respiratory care, it ranked 19th globally and first in South Korea for the third consecutive year. The hospital also placed fifth in digestive diseases and tenth in urology, with a total of 12 clinical departments ranking within the global top 100.
In the smart hospital category, which assesses medical IT infrastructure and the adoption of digital technologies, Samsung Seoul retained its domestic lead for the fifth consecutive year and climbed three spots to 15th globally. The hospital has implemented a digital twin-based operating system, known as DOCC, to simulate resource allocation and patient flow, enhancing operational efficiency in real-world clinical settings.
Samsung Seoul has made significant strides in oncology, particularly in precision medicine. In 2022, the hospital treated approximately 30,000 cancer patients, achieving a five-year survival rate of 75%. For lung cancer specifically, the hospital reported a five-year relative survival rate of 63.6%. The institution has also built a robust database for precision cancer care and consistently documented treatment outcomes across various cancer types.
Hospital President Seung-Woo Park emphasized the significance of the recognition. “This evaluation provided an opportunity for our clinical practices and operational systems to be scrutinized on an international stage,” Park said. “We are committed to continuous improvement and collaboration moving forward.”
The hospital’s achievements underscore South Korea’s growing prominence in global healthcare, with Samsung Seoul leading the charge in both clinical excellence and technological innovation.
Lim Hye Jung, HEALTH IN NEWS TEAM
press@hinews.co.kr
